Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with intermediate age-related macular degeneration (a mid-stage eye condition affecting the retina) in one or both eyes
- People whose study eye has a specific higher-risk form of this condition, involving a large number of deposits under the retina (called drusen) covering a certain area of the eye, with no sign of advanced disease such as geographic atrophy (a type of tissue loss) or abnormal blood vessel growth in that eye
- People where both eyes have this higher-risk intermediate stage of the condition, OR where one eye has the higher-risk intermediate stage and the other eye has more advanced disease (either geographic atrophy or abnormal blood vessel growth)
Who may not be able to join:
- People who have previously taken high-dose Atorvastatin 80 mg (a cholesterol-lowering medication)
- People who have previously taken other cholesterol-lowering medications in the same drug family (statins), where their primary doctor feels it would not be safe to switch them to high-dose Atorvastatin, or where high-dose Atorvastatin is considered unsuitable for them by their doctor
- People who have had a known bad reaction to statin medications
- People who have serious kidney disease or multiple significant health conditions
- People over the age of 85
- People who are pregnant
- People currently taking a medication called cyclosporine (often used to suppress the immune system)
- People with active inflammation inside the eye (uveitis)
- People with a current eye infection
- People who have a retinal condition other than age-related macular degeneration
- People who have cloudiness or blockages within the eye that affect vision clarity
- People with a significant prescription for glasses or contact lenses (a refractive error of 6 diopters or more)
- People who have had previous surgery on the retina
- People who have had other eye surgery or a procedure inside the study eye (other than anti-VEGF injections for abnormal blood vessel growth) within the 90 days before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John B Miller, MD, Massachusetts Eye and Ear Infirmary, Harvard Medical School
Phone: 617-573-3750
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Dark Adaptation recovery time measured by change in Rod Intercept time (RIT); Change in drusen volume measured by Spectral Domain OCT; To correlate visual functions of dark adaption with change in drusen volume
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.